Small molecule · Inhibitor of poly(ADP-ribose) polymerase 1 (PARP1) · developed by GILEAD SCIENCES
GS-0201 is an orally bioavailable small molecule that selectively binds and inhibits PARP1, a nuclear enzyme involved in repairing DNA single-strand and double-strand breaks. By blocking base excision repair, it promotes DNA strand break accumulation and genomic instability, leading to apoptosis. It is being studied in advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06167317 | Phase 1 | Advanced Solid Tumors | Recruiting | GILD |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid Tumors
See GILD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
GILD catalysts and pipeline →